Trials / Terminated
TerminatedNCT00259363
Oxaliplatin in Rectal Cancer
Phase I-II Study of Preoperative Oxaliplatin-FU and Radiotherapy for Patients With Rectal Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
* Phase I: To determine the maximum tolerated dose, and recommended dose of the proposed doses of oxaliplatin in this study * Phase II: To determine the treatment efficacy according to response rates from phase I.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxaliplatin | oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2006-06-01
- First posted
- 2005-11-29
- Last updated
- 2009-12-07
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00259363. Inclusion in this directory is not an endorsement.